[A new topical carbonic anhydrase inhibitor (MK-927). Tolerance comparison with betaxolol in healthy probands].
MK-927 is a new topical carboanhydrase inhibitor with proven ability to lower intraocular pressure in glaucoma patients. Subjective and objective symptoms following topical application of MK-927 were evaluated in a randomized, double-blind, placebo-controlled study in which 24 healthy male volunteers took part. Symptoms were rated according to a visual analog scale by the volunteers and according to a grading scale by the examiner. The study showed good local tolerance of MK-927, comparable to that of Betaxolol.
Feicht
B
B
Augenklinik und -poliklinik rechts der Isar der Technischen Universität München.
Hofmann
H M
HM
Lippa
E
E
Brunner-Ferber
F
F
von Denffer
H
H
Merté
H J
HJ
D000287:Administration, Topical; D015784:Betaxolol / Q000008:administration & dosage / Q000494:pharmacology*; D002257:Carbonic Anhydrase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D004311:Double-Blind Method; D004361:Drug Tolerance; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D013449:Sulfonamides / Q000008:administration & dosage / Q000494:pharmacology*; D013876:Thiophenes / Q000008:administration & dosage / Q000494:pharmacology*; D013997:Time Factors
D002257:Carbonic Anhydrase Inhibitors; D013449:Sulfonamides; D013876:Thiophenes; C057921:sezolamide; D015784:Betaxolol
Ein neuer, lokal anwendbarer Carboanhydrasehemmer (MK-927). Toleranzvergleich mit Betaxolol bei gesunden Probanden.